Autoimmune Haemolytic Anaemia (AIHA) is a challenging condition. The disease frequently relapses because of persistent autoreactive B-cell activity. Multirefractory AIHA, an advanced stage, resists at least three lines of prior therapy. Therefore, finding an effective, long-lasting treatment remains a critical unmet need for haematologists. However, a new study offers substantial hope. Single-infusion CD19 CAR T-cell AIHA therapy demonstrates profound B-cell depletion, leading to sustained drug-free remission in these difficult-to-treat patients.
Understanding the Need for CAR T-cell AIHA in Refractory Disease
Conventional AIHA treatments, which often include corticosteroids and rituximab, show high initial response rates. Nonetheless, many patients require continuous, high-dose therapy or relapse quickly. Because of this, physicians must often rely on third-line options like splenectomy or potent immunosuppressants. Multirefractory AIHA represents a treatment failure state, requiring a strategy to “reset” the immune system. CD19 CAR T-cell therapy targets B cells, which are the source of the autoantibodies causing hemolysis. Consequently, this innovative approach aims for drug-free remission rather than continuous suppression.
The recent clinical trial enrolled 11 patients who had primary multirefractory AIHA. This group included individuals from both a compassionate-use program and a phase 1 study. Researchers gave each patient a single infusion of autologous CD19 CAR T cells. The primary goal assessed the safety profile, including adverse events like cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Furthermore, secondary objectives tracked efficacy and pharmacokinetic features.
Outstanding Efficacy and Manageable Safety Profile
The results show remarkable efficacy. All 11 patients achieved a complete response. A complete response was defined by symptom resolution, increased haemoglobin, and normalised haemolysis markers. In fact, the median time to complete a response was only 45 days. This is a rapid improvement for a multirefractory condition. Moreover, the median duration of drug-free remission lasted 11.5 months.
The treatment’s safety profile proved manageable. Specifically, cytokine-release syndrome occurred in 9 patients, but only at grade 1 or 2 severity. Furthermore, one patient experienced grade 1 immune effector cell-associated neurotoxicity syndrome. The study recorded 15 total infections among 7 patients, yet none were classified as grade 4 or higher. One patient did have grade 3 immune effector cell-associated hematotoxicity. Overall, the therapy exhibited expected toxic effects while providing sustained remission.
Insights into Immune System Reset and Relapse
The study also employed advanced multi-omics techniques. These methods included flow cytometry, single-cell RNA sequencing, and B-cell receptor sequencing. This analysis provided critical insights into the mechanism of action. Patients in drug-free remission showed a predominance of naive B cells in the reconstituted B-cell population. Conversely, one patient who relapsed showed a unique mechanism. Crosstalk between HLA-DRB5+ B cells, CD4+ T cells, and B-cell maturation antigen-expressing long-lived plasma cells created a specific B-cell niche. This discovery may guide future strategies to prevent relapse in the future.
Frequently Asked Questions
Q1: How is multirefractory AIHA defined in this study?
Multirefractory AIHA is defined as an advanced stage of Autoimmune Hemolytic Anaemia in patients who have failed to respond to at least three lines of prior therapy.
Q2: What was the complete response rate and duration of remission?
The study reported a 100% complete response rate. The median duration of drug-free remission was 11.5 months (range, 6.8 to 21.0 months).
Q3: What were the most significant side effects observed?
The most common significant adverse events were cytokine-release syndrome (CRS) of grade 1 or 2 in nine patients and infections (grade 3 or lower) in seven patients. Only one patient developed grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS).
References
- Li R et al. CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anaemia. N Engl J Med. 2026 Jan 15. doi: 10.1056/NEJMoa2509820. PMID: 41534043.
- Barcellini W et al. Diagnosis and treatment of autoimmune hemolytic anaemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020.
- CAR T-cell therapy in autoimmune diseases: A breakthrough in treatment. drdhaiwat.com. 2025.